Metabolic alterations associated with schizophrenia: A critical evaluation of proton magnetic resonance spectroscopy studies

Journal of Neurochemistry

Volumn 128, Issue 1, 2014, Pages 1-87

  Schwerk, Anne ^a   Alves, Fabiana D S ^b   Pouwels, Petra J W ^c   Van Amelsvoort, Therese ^d  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

1H MRS; imaging; proton spectroscopy; psychosis; schizophrenia; spectroscopy

Indexed keywords

4 AMINOBUTYRIC ACID; ATYPICAL ANTIPSYCHOTIC AGENT; CHOLINE; CREATINE; GLUTAMIC ACID; GLUTAMINE; HALOPERIDOL; INOSITOL; N ACETYLASPARTIC ACID; N ACETYLASPARTYLGLUTAMIC ACID; NEUROLEPTIC AGENT; QUETIAPINE;

BASAL GANGLION; BRAIN METABOLISM; CEREBELLUM; CINGULATE GYRUS; CORPUS CALLOSUM; DISEASE ASSOCIATION; FRONTAL CORTEX; HIPPOCAMPUS; HUMAN; MEDIAL PREFRONTAL CORTEX; METABOLITE; NEUROIMAGING; NEUROPATHOLOGY; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; REVIEW; SCHIZOPHRENIA; SYSTEMATIC REVIEW; TEMPORAL LOBE; THALAMUS;

1H-MRS; IMAGING; PROTON SPECTROSCOPY; PSYCHOSIS; SCHIZOPHRENIA; SPECTROSCOPY;

BRAIN; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; PROTONS; SCHIZOPHRENIA;

EID: 84890805338     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/jnc.12398     Document Type: Review

References (167)

1. Ando K., Takei N., Matsumoto H., Iyo M., Isoda H., and, Mori N., (2002) Neural damage in the lenticular nucleus linked with tardive dyskinesia in schizophrenia: a preliminary study using proton magnetic resonance spectroscopy. Schizophr. Res. 57, 273-279. (Pubitemid 35240030)
2. Aoyama N., Théberge J., Drost D. J., et al,. (2011) Grey matter and social functioning correlates of glutamatergic metabolite loss in schizophrenia. Br. J. Psychiatry 198, 448-456.
3. Auer D. P., Wilke M., Grabner A., Heidenreich J. O., Bronisch T., and, Wetter T. C., (2001) Reduced NAA in the thalamus and altered membrane and glial metabolism in schizophrenic patients detected by 1H-MRS and tissue segmentation. Schizophr. Res. 52, 87-99. (Pubitemid 32947051)
4. Aydin K., Ucok A., and, Cakir S., (2007) Quantitative proton MR spectroscopy findings in the corpus callosum of patients with schizophrenia suggest callosal disconnection. AJNR Am. J. Neuroradiol. 28, 1968-1974. (Pubitemid 350174744)
5. Aydin K., Ucok A., and, Guler J., (2008) Altered metabolic integrity of corpus callosum among individuals at ultra high risk of schizophrenia and first-episode patients. Biol. Psychiatry 64, 750-757.
6. Barker P. B., (2001) N-acetyl aspartate-a neuronal marker? Ann. Neurol. 49, 423-424. (Pubitemid 32281325)
7. Bartha R., Drost D. J., and, Williamson P. C., (1999) Factors affecting the quantification of short echo in-vivo 1H MR spectra: prior knowledge, peak elimination, and filtering. NMR Biomed. 12, 205-216. (Pubitemid 29325667)
8. Basoglu C., Cetin M., Oner O., Ebrinc S., Semiz U. B., Kandilcioglu H., Silit E., and, Kizilkaya E., (2006) Comparison of right thalamus and temporal cortex metabolite levels of drug-naive first-episode psychotic and chronic schizophrenia in patients. Turk Psikiyatri Derg. 17, 85-91.
9. Berger G. E., Wood S. J., Wellard R. M., et al,. (2008) Ethyl-eicosapentaenoic acid in first-episode psychosis. A 1H-MRS study. Neuropsychopharmacology 33, 2467-2473.
10. Bertolino A., and, Weinberger D. R., (1999) Proton magnetic resonance spectroscopy in schizophrenia. Eur. J. Radiol. 30, 132-141. (Pubitemid 29281714)
11. Bertolino A., Callicott J. H., Mattay V. S., Weidenhammer K. M., Rakow R., Egan M. F., and, Weinberger D. R., (2001) The effect of treatment with antipsychotic drugs on brain N-acetylaspartate measures in patients with schizophrenia. Biol. Psychiatry 49, 39-46. (Pubitemid 32332952)
12. Bertolino A., Sciota D., Brudaglio F., et al,. (2003) Working memory deficits and levels of N-acetylaspartate in patients with schizophreniform disorder. Am. J. Psychiatry 160, 483-489. (Pubitemid 41094256)
13. Blatter D. D., Bigler E. D., Gale S. D., Johnson S. C., Anderson C. V., Burnett B. M., Parker N., Kurth S., and, Horn S. D., (1995) Quantitative volumetric analysis of brain MR: normative database spanning 5 decades of life. AJNR Am. J. Neuroradiol. 16, 241-251.
14. Block W., Bayer T. A., Tepest R., et al,. (2000) Decreased frontal lobe ratio of N-acetyl aspartate to choline in familial schizophrenia: a proton magnetic resonance spectroscopy study. Neurosci. Lett. 289, 147-151. (Pubitemid 30440647)
15. Bloemen O. J., Gleich T., de Koning M. B., da Silva Alvis F., de Haan L., Linszen D. H., Booij J., and, van Amelsvoort T. A., (2011) Hippocampal glutamate levels and striatal dopamine D(2/3) receptor occupancy in subjects at ultra high risk of psychosis. Biol. Psychiatry 70, e1-e2; author reply e3.
16. Bogner W., Gruber S., Doelken M., et al,. (2010) In vivo quantification of intracerebral GABA by single-voxel (1)H-MRS-How reproducible are the results? Eur. J. Radiol. 73, 526-531.
17. Braus D. F., Ende G., Weber-Fahr W., Demirakca T., Tost H., and, Henn F. A., (2002) Functioning and neuronal viability of the anterior cingulate neurons following antipsychotic treatment: MR-spectroscopic imaging in chronic schizophrenia. Eur. Neuropsychopharmacol. 12, 145-152. (Pubitemid 34168480)
18. Brief E. E., Moll R., Li D. K., and, Mackay A. L., (2009) Absolute metabolite concentrations calibrated using the total water signal in brain (1)H MRS. NMR Biomed. 22, 349-354.
19. Bustillo J. R., Rowland L. M., Jung R., Brooks W. M., Qualls C., Hammond R., Hart B., and, Lauriello J., (2008) Proton magnetic resonance spectroscopy during initial treatment with antipsychotic medication in schizophrenia. Neuropsychopharmacology: official publication of the American College of. Neuropsychopharmacology 33, 2456-2466.
20. Bustillo J. R., Rowland L. M., Mullins P., Jung R., Chen H., Qualls C., Hammond R., Brooks W. M., and, Lauriello J., (2010) 1H-MRS at 4 tesla in minimally treated early schizophrenia. Mol. Psychiatry 15, 629-636.
21. Bustillo J. R., Chen H., Gasparovic C., Mullins P., Caprihan A., Qualls C., Apfeldorf W., Lauriello J., and, Posse S., (2010) Glutamate as a marker of cognitive function in schizophrenia: a proton spectroscopic imaging study at 4 Tesla. Biol. Psychiatry 69, 19-27.
22. Byne W., Hazlett E. A., Buchsbaum M. S., and, Kemether E., (2009) The thalamus and schizophrenia: current status of research. Acta Neuropathol. 117, 347-368.
23. Callicott J. H., Egan M. F., Bertolino A., Mattay V. S., Langheim F. J., Frank J. A., and, Weinberger D. R., (1998) Hippocampal N-acetyl aspartate in unaffected siblings of patients with schizophrenia: a possible intermediate neurobiological phenotype. Biol. Psychiatry 44, 941-950. (Pubitemid 28545222)
24. Callicott J. H., Bertolino A., Egan M. F., Mattay V. S., Langheim F. J., and, Weinberger D. R., (2000) Selective relationship between prefrontal N-acetylaspartate measures and negative symptoms in schizophrenia. Am. J. Psychiatry 157, 1646-1651.
25. Callicott J. H., Egan M. F., Mattay V. S., Bertolino A., Bone A. D., Verchinksi B., and, Weinberger D. R., (2003) Abnormal fMRI response of the dorsolateral prefrontal cortex in cognitively intact siblings of patients with schizophrenia. Am. J. Psychiatry 160, 709-719. (Pubitemid 41079604)
26. Canuso C. M., and, Pandina G., (2007) Gender and schizophrenia. Psychopharmacol. Bull. 40, 178-190.
27. Carlsson A., Waters N., and, Carlsson M. L., (1999) Neurotransmitter interactions in schizophrenia-therapeutic implications. Eur. Arch. Psychiatry Clin. Neurosci. 249 (Suppl 4), 37-43.
28. Chan R. C., Di X., McAlonan G. M., and, Gong Q. Y., (2011) Brain anatomical abnormalities in high-risk individuals, first-episode, and chronic schizophrenia: an activation likelihood estimation meta-analysis of illness progression. Schizophr. Bull. 37, 177-188.
29. Chang L., Friedman J., Ernst T., Zhong K., Tsopelas N. D., and, Davis K., (2007) Brain metabolite abnormalities in the WM of elderly schizophrenic subjects: implication for glial dysfunction. Biol. Psychiatry 62, 1396-1404. (Pubitemid 350180729)
30. Chen X., Sachdev P. S., Wen W., and, Anstey K. J., (2007) Sex differences in regional gray matter in healthy individuals aged 44-48 years: a voxel-based morphometric study. NeuroImage 36, 691-699. (Pubitemid 46907644)
31. Clark J. B., (1998) N-acetyl aspartate: a marker for neuronal loss or mitochondrial dysfunction. Dev. Neurosci. 20, 271-276.
32. Cosgrove K. P., Mazure C. M., and, Staley J. K., (2007) Evolving knowledge of sex differences in brain structure, function, and chemistry. Biol. Psychiatry 62, 847-855. (Pubitemid 47488220)
33. Csernansky J. G., Schindler M. K., Splinter N. R., et al,. (2004) Abnormalities of thalamic volume and shape in schizophrenia. Am. J. Psychiatry 161, 896-902. (Pubitemid 38625344)
34. Dager S. R., Corrigan N. M., Richards T. L., and, Posse S., (2008) Research applications of magnetic resonance spectroscopy to investigate psychiatric disorders. Top. Magn. Reson. Imaging 19, 81-96.
35. Deicken R. F., Johnson C., Eliaz Y., and, Schuff N., (2000) Reduced concentrations of thalamic N-acetylaspartate in male patients with schizophrenia. Am. J. Psychiatry 157, 644-647. (Pubitemid 30191210)
36. Deicken R. F., Feiwell R., Schuff N., and, Soher B., (2001) Evidence for altered cerebellar vermis neuronal integrity in schizophrenia. Psychiatry Res. 107, 125-134. (Pubitemid 32868798)
37. Delamillieure P., Fernandez J., Constans J. M., et al,. (2000) Proton magnetic resonance spectroscopy of the medial prefrontal cortex in patients with deficit schizophrenia: preliminary report. Am. J. Psychiatry 157, 641-643. (Pubitemid 30191209)
38. Do K. Q., Trabesinger A. H., Kirsten-Kruger M., Lauer C. J., Dydak U., Hell D., Holsboer F., Boesiger P., and, Cuenod M., (2000) Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo. Eur. J. Neurosci. 12, 3721-3728.
39. Drost D. J., Riddle W. R., and, Clarke G. D., (2002) Proton magnetic resonance spectroscopy in the brain: report of AAPM MR Task Group #9. Med. Phys. 29, 2177-2197.
40. Ellison-Wright I., and, Bullmore E., (2009) Meta-analysis of diffusion tensor imaging studies in schizophrenia. Schizophr. Res. 108, 3-10.
41. van Elst L. T., Valerius G., Büchert M., Thiel T., Rüsch N., Bubl E., Hennig J., Ebert D., and, Olbrich H. M., (2005) Increased prefrontal and hippocampal glutamate concentration in schizophrenia: evidence from a magnetic resonance spectroscopy study. Biol. Psychiatry 1, 724-730. (Pubitemid 41547240)
42. Ende G., Braus D. F., Walter S., Weber-Fahr W., Soher B., Maudsley A. A., and, Henn F. A., (2000) Effects of age, medication, and illness duration on the N-acetyl aspartate signal of the anterior cingulate region in schizophrenia. Schizophr. Res. 41, 389-395. (Pubitemid 30109595)
43. Fannon D., Simmons A., Tennakoon L., O'Ceallaigh S., Sumich A., Doku V., Shew C., and, Sharma T., (2003) Selective deficit of hippocampal N-acetylaspartate in antipsychotic-naive patients with schizophrenia. Biol. Psychiatry 54, 587-598. (Pubitemid 41115095)
44. Farber N. B., (2003) The NMDA receptor hypofunction model of psychosis. Ann. N. Y. Acad. Sci. 1003, 119-130. (Pubitemid 38083050)
45. Fornito A., Yucel M., and, Pantelis C., (2009) Reconciling neuroimaging and neuropathological findings in schizophrenia and bipolar disorder. Curr. Opin. Psychiatry 22, 312-319.
46. Frahm J., Bruhn H., Gyngell M. L., Merboldt K. D., Hänicke W., and, Sauter R., (1989) Localized high-resolution proton NMR spectroscopy using stimulated echoes: initial applications to human brain in vivo. Magn. Reson. Med. 9, 79-93. (Pubitemid 19044561)
47. de la Fuente-Sandoval C., Favila R., Alvarado P., Leon-Ortiz P., Diaz-Galvis L., Amezcua C., Garcia-Munoz E., and, Graff-Guerrero A., (2009) Glutamate increase in the associative striatum in schizophrenia: a longitudinal magnetic resonance spectroscopy preliminary study. Gac. Med. Mex. 145, 109-113.
48. de la Fuente-Sandoval C., Leon-Ortiz P., Favila R., Stephano S., Mamo D., Ramirez-Bermudez J., and, Graff-Guerrero A., (2011) Higher levels of glutamate in the associative-striatum of subjects with prodromal symptoms of schizophrenia and patients with first-episode psychosis. Neuropsychopharmacology 36, 1781-1791.
49. Fujiwara H., Shimizu M., Hirao K., Miyata J., Namiki C., Sawamoto N., Fukuyama H., Hayashi T., and, Murai T., (2008) Female specific anterior cingulate abnormality and its association with empathic disability in schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 32, 1728-1734.
50. Fukuzako H., (2000) Heritability heightens brain metabolite differences in schizophrenia. J. Neuropsychiatry Clin. Neurosci. 12, 95-97. (Pubitemid 30093696)
51. Fusar-Poli P., Perez J., Broome M., et al,. (2007) Neurofunctional correlates of vulnerability to psychosis: a systematic review and meta-analysis. Neurosci. Biobehav. Rev. 31, 465-484. (Pubitemid 46527879)
52. Fusar-Poli P., Howes O., Valli I., Allen P., Broome M., Grasby P., and, McGuire P., (2009) Multimodal functional imaging investigation before and after the onset of psychosis. Int. J. Neuropsychopharmacol. 12, 579-581.
53. Galinska B., Szulc A., Tarasow E., Kubas B., Dzienis W., Czernikiewicz A., and, Walecki J., (2009) Duration of untreated psychosis and proton magnetic resonance spectroscopy (1H-MRS) findings in first-episode schizophrenia. Med. Sci. Monit. 15, CR82-CR88.
54. Gillies R. J., (1992) Nuclear magnetic resonance and its applications to physiological problems. Annu. Rev. Physiol. 54, 733-748.
55. Gimenez M., Junque C., Perez M., Vendrell P., Baeza I., Salamero M., Mercader J. M., and, Bernardo M., (2003) Basal ganglia N-acetylaspartate correlates with the performance in the procedural task 'Tower of Hanoi' of neuroleptic-naive schizophrenic patients. Neurosci. Lett. 347, 97-100. (Pubitemid 36836225)
56. Goto N., Yoshimura R., Moriya J., et al,. (2009) Reduction of brain gamma-aminobutyric acid (GABA) concentrations in early-stage schizophrenia patients: 3T Proton MRS study. Schizophr. Res. 112, 192-193.
57. Goto N., Yoshimura R., Kakeda S., et al,. (2010) No alterations of brain GABA after 6 months of treatment with atypical antipsychotic drugs in early-stage first-episode schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 34, 1480-1483.
58. Goto N., Yoshimura R., Kakeda S., et al,. (2011) Comparison of brain N-acetylaspartate levels and serum brain-derived neurotrophic factor (BDNF) levels between patients with first-episode schizophrenia psychosis and healthy controls. Eur. Psychiatry 26, 57-63.
59. Govindaraju V., Young K., and, Maudsley A. A., (2000) Proton NMR chemical shifts and coupling constants for brain metabolites. NMR Biomed. 13, 129-153. (Pubitemid 30414704)
60. Gur R. C., Turetsky B. I., Matsui M., Yan M., Bilker W., Hughett P., and, Gur R. E., (1999) Sex differences in brain gray and white matter in healthy young adults: correlations with cognitive performance. J. Neurosci. 19, 4065-4072. (Pubitemid 29222278)
61. Hammen T., and, Stefan H., (2004) (1)H MR spectroscopy. Methods and applications in diagnosis and assessment of surgical and conservative treatment strategies in epilepsies. Nervenarzt 75, 970-983. (Pubitemid 39468509)
62. Hardy C. J., Tal A., Babb J. S., Perry N. N., Messinger J. W., Antonius D., Malaspina D., and, Gonen O., (2011) Multivoxel proton MR spectroscopy used to distinguish anterior cingulate metabolic abnormalities in patients with schizophrenia. Radiology 261, 542-550.
63. Harms M. P., Wang L., Mamah D., Barch D. M., Thompson P. A., and, Csernansky J. G., (2007) Thalamic shape abnormalities in individuals with schizophrenia and their nonpsychotic siblings. J. Neurosci. 27, 13835-13842. (Pubitemid 350278275)
64. Hasan A., Wobrock T., Falkai P., et al,. (2011) Hippocampal integrity and neurocognition in first-episode schizophrenia: a multidimensional study. World J. Biol. Psychiatry [Epub ahead of print].
65. He Z. L., Deng W., Li M. L., Chen Z. F., Collier D. A., Ma X., and, Li T., (2012) Detection of metabolites in the white matter of frontal lobes and hippocampus with proton in first-episode treatment-naive schizophrenia patients. Early Interv. Psychiatry 6, 166-175.
66. Hirvonen J., van Erp T. G., Huttunen J., et al,. (2005) Increased caudate dopamine D2 receptor availability as a genetic marker for schizophrenia. Arch. Gen. Psychiatry 62, 371-378. (Pubitemid 40471686)
67. Honea R., Crow T. J., Passingham D., and, Mackay C. E., (2005) Regional deficits in brain volume in schizophrenia: a meta-analysis of voxel-based morphometry studies. Am. J. Psychiatry 162, 2233-2245. (Pubitemid 41740200)
68. Hurd R., Sailasuta N., Srinivasan R., Vigneron D. B., Pelletier D., and, Nelson S. J., (2004) Measurement of brain glutamate using TE-averaged PRESS at 3T. Magn. Reson. Med. 51, 435-440. (Pubitemid 38298653)
69. Inglese M., Spindler M., Babb J. S., Sunenshine P., Law M., and, Gonen O., (2006) Field, coil, and echo-time influence on sensitivity and reproducibility of brain proton MR spectroscopy. AJNR Am. J. Neuroradiol. 27, 684-688. (Pubitemid 44897798)
70. Jakary A., Vinogradov S., Feiwell R., and, Deicken R. F., (2005) N-acetylaspartate reductions in the mediodorsal and anterior thalamus in men with schizophrenia verified by tissue volume corrected proton MRSI. Schizophr. Res. 76, 173-185. (Pubitemid 40804764)
71. Jansen J. F., Backes W. H., Nicolay K., and, Kooi M. E., (2006) 1H MR spectroscopy of the brain: absolute quantification of metabolites. Radiology 240, 318-332. (Pubitemid 44098628)
72. Jessen F., Scherk H., Traber F., et al,. (2006) Proton magnetic resonance spectroscopy in subjects at risk for schizophrenia. Schizophr. Res. 87, 81-88. (Pubitemid 44428131)
73. Jessen F., Fingerhut N., Sprinkart A. M., et al,. (2013) N-acetylaspartylglutamate (NAAG) and N-acetylaspartate (NAA) in patients with schizophrenia. Schizophr. Bull. 39, 197-205.
74. Kapur S., Mizrahi R., and, Li M., (2005) From dopamine to salience to psychosis-linking biology, pharmacology and phenomenology of psychosis. Schizophr. Res. 79, 59-68. (Pubitemid 41362593)
75. Kegeles L. S., Shungu D. C., Anjilvel S., et al,. (2000) Hippocampal pathology in schizophrenia: magnetic resonance imaging and spectroscopy studies. Psychiatry Res. 98, 163-175. (Pubitemid 30255912)
76. Kegeles L. S., Mao X., Stanford A. D., et al,. (2012) Elevated prefrontal cortex gamma-aminobutyric acid and glutamate-glutamine levels in schizophrenia measured in vivo with proton magnetic resonance spectroscopy. Arch. Gen. Psychiatry 69, 449-459.
77. Klar A. A., Ballmaier M., Leopold K., Hake I., Schaefer M., Bruhl R., Schubert F., and, Gallinat J., (2010) Interaction of hippocampal volume and N-acetylaspartate concentration deficits in schizophrenia: a combined MRI and 1H-MRS study. NeuroImage 53, 51-57.
78. Kreis R., (2004) Issues of spectral quality in clinical 1H-magnetic resonance spectroscopy and a gallery of artifacts. NMR Biomed. 17, 361-381. (Pubitemid 39335175)
79. Kreis R., Ernst T., and, Ross B. D., (1993) Development of the human brain: in vivo quantification of metabolite and water content with proton magnetic resonance spectroscopy. Magn. Reson. Med. 30, 424-437. (Pubitemid 23300070)
80. Kreis R., Slotboom J., Hofmann L., and, Boesch C., (2005) Integrated data acquisition and processing to determine metabolite contents, relaxation times, and macromolecule baseline in single examinations of individual subjects. Magn. Reson. Med. 54, 761-768. (Pubitemid 41457045)
81. Li B. S., Wang H., and, Gonen O., (2003) Metabolite ratios to assumed stable creatine level may confound the quantification of proton brain MR spectroscopy. Magn. Reson. Imaging 21, 923-928. (Pubitemid 37377485)
82. Lui S., Deng W., Huang X., et al,. (2009) Neuroanatomical differences between familial and sporadic schizophrenia and their parents: an optimized voxel-based morphometry study. Psychiatry Res. 171, 71-81.
83. Lutkenhoff E. S., van Erp T. G., Thomas M. A., et al,. (2010) Proton MRS in twin pairs discordant for schizophrenia. Mol. Psychiatry 15, 308-318.
84. Mamah D., Harms M. P., Wang L., Barch D., Thompson P., Kim J., Miller M. I., and, Csernansky J. G., (2008) Basal ganglia shape abnormalities in the unaffected siblings of schizophrenia patients. Biol. Psychiatry 64, 111-120.
85. Marshall I., Wardlaw J., Cannon J., Slattery J., and, Sellar R. J., (1996) Reproducibility of metabolite peak areas in 1H MRS of brain. Magn. Reson. Imaging 14, 281-292. (Pubitemid 26181447)
86. Martinez-Granados B., Brotons O., Martinez-Bisbal M. C., Celda B., Marti-Bonmati L., Aguilar E. J., Gonzalez J. C., and, Sanjuan J., (2008) Spectroscopic metabolomic abnormalities in the thalamus related to auditory hallucinations in patients with schizophrenia. Schizophr. Res. 104, 13-22.
87. Matsuzawa D., Obata T., Shirayama Y., et al,. (2008) Negative correlation between brain glutathione level and negative symptoms in schizophrenia: a 3T 1H-MRS study. PLoS One 3, e1944.
88. Maudsley A. A., Domenig C., Govind V., Darkazanli A., Studholme C., Arheart K., and, Bloomer C., (2009) Mapping of brain metabolite distributions by volumetric proton MR spectroscopic imaging (MRSI). Magn. Reson. Med. 61, 548-559.
89. Michaelis T., Merboldt K. D., Bruhn H., Hanicke W., and, Frahm J., (1993) Absolute concentrations of metabolites in the adult human brain in vivo: quantification of localized proton MR spectra. Radiology 187, 219-227. (Pubitemid 23097888)
90. Miyaoka T., Yasukawa R., Mizuno S., Sukegawa T., Inagaki T., Horiguchi J., Seno H., Oda K., and, Kitagaki H., (2005) Proton magnetic resonance spectroscopy (1H-MRS) of hippocampus, basal ganglia, and vermis of cerebellum in schizophrenia associated with idiopathic unconjugated hyperbilirubinemia (Gilbert's syndrome). J. Psychiatr. Res. 39, 29-34. (Pubitemid 39422283)
91. Moffett J. R., and, Namboodiri M. A., (1995) Differential distribution of N-acetylaspartylglutamate and N-acetylaspartate immunoreactivities in rat forebrain. J. Neurocytol. 24, 409-433.
92. Molina V., Sanchez J., Reig S., et al,. (2005) N-acetyl-aspartate levels in the dorsolateral prefrontal cortex in the early years of schizophrenia are inversely related to disease duration. Schizophr. Res. 73, 209-219. (Pubitemid 40093881)
93. Moore C. M., Bonello C. M., Sherwood A. R., Cohen B. M., Renshaw P. F., and, Yurgulen-Todd D. A., (2002) Mesial temporal lobe Cho to Cr(PCr) ratio asymmetry in chronic schizophrenics. Schizophr. Res. 57, 35-42.
94. Morche S., (2005) Single-Voxel- versus Multi-Voxel Protonen-MR- Spektroskopie bei verschiedenen intrakraniellen Läsionen. University Würzburg, Würzburg.
95. Moreno D., Burdalo M., Reig S., Parellada M., Zabala A., Desco M., Baca-Baldomero E., and, Arango C., (2005) Structural neuroimaging in adolescents with a first psychotic episode. J. Am. Acad. Child Adolesc. Psychiatry 44, 1151-1157. (Pubitemid 41508127)
96. Narr K. L., Thompson P. M., Sharma T., et al,. (2001) Three-dimensional mapping of temporo-limbic regions and the lateral ventricles in schizophrenia: gender effects. Biol. Psychiatry 50, 84-97. (Pubitemid 32728208)
97. Novotny E. J. Jr, Fulbright R. K., Pearl P. L., Gibson K. M., and, Rothman D. L., (2003) Magnetic resonance spectroscopy of neurotransmitters in human brain. Ann. Neurol. 54 (Suppl 6), S25-S31. (Pubitemid 36903851)
98. Ohara K., Isoda H., Suzuki Y., Takehara Y., Ochiai M., Takeda H., Hattori K., Igarashi Y., and, Ohara K., (2000) Proton magnetic resonance spectroscopy of lenticular nuclei in simple schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 24, 507-519. (Pubitemid 30419076)
99. Ohrmann P., Siegmund A., Suslow T., et al,. (2007) Cognitive impairment and in vivo metabolites in first-episode neuroleptic-naive and chronic medicated schizophrenic patients: a proton magnetic resonance spectroscopy study. J. Psychiatr. Res. 41, 625-634. (Pubitemid 46509646)
100. Ohrmann P., Kugel H., Bauer J., et al,. (2008) Learning potential on the WCST in schizophrenia is related to the neuronal integrity of the anterior cingulate cortex as measured by proton magnetic resonance spectroscopy. Schizophr. Res. 106, 156-163.
101. Olbrich H. M., Valerius G., Rusch N., Buchert M., Thiel T., Hennig J., Ebert D., and, Van Elst L. T., (2008) Frontolimbic glutamate alterations in first episode schizophrenia: evidence from a magnetic resonance spectroscopy study. World J. Biol. Psychiatry 9, 59-63. (Pubitemid 351250521)
102. Omori M., Murata T., Kimura H., Koshimoto Y., Kado H., Ishimori Y., Ito H., and, Wada Y., (2000) Thalamic abnormalities in patients with schizophrenia revealed by proton magnetic resonance spectroscopy. Psychiatry Res. 98, 155-162. (Pubitemid 30255911)
103. O'Neill J., Levitt J., Caplan R., Asarnow R., McCracken J. T., Toga A. W., and, Alger J. R., (2004) 1H MRSI evidence of metabolic abnormalities in childhood-onset schizophrenia. NeuroImage 21, 1781-1789. (Pubitemid 38446598)
104. Ongur D., Prescot A. P., Jensen J. E., Cohen B. M., and, Renshaw P. F., (2009) Creatine abnormalities in schizophrenia and bipolar disorder. Psychiatry Res. 172, 44-48.
105. Ongur D., Prescot A. P., Jensen J. E., Rouse E. D., Cohen B. M., Renshaw P. F., and, Olson D. P., (2010a) T2 relaxation time abnormalities in bipolar disorder and schizophrenia. Magn. Reson. Med. 63, 1-8.
106. Ongur D., Prescot A. P., McCarthy J., Cohen B. M., and, Renshaw P. F., (2010b) Elevated gamma-aminobutyric acid levels in chronic schizophrenia. Biol. Psychiatry 68, 667-670.
107. Ota M, Ishikawa M, Sato N, Hori H, Sasayama D, Hattori K, Teraishi T, Nakata Y, and, Kunugi H., (2012) Glutamatergic changes in the cerebral white matter associated with schizophrenic exacerbation. Acta Psychiatr. Scand. 126, 72-78.
108. Pfefferbaum A., Adalsteinsson E., Spielman D., Sullivan E. V., and, Lim K. O., (1999) In vivo spectroscopic quantification of the N-acetyl moiety, creatine, and choline from large volumes of brain gray and white matter: effects of normal aging. Magn. Reson. Med. 41, 276-284. (Pubitemid 29104512)
109. Pfeuffer J., Tkac I., Provencher S. W., and, Gruetter R., (1999) Toward an in vivo neurochemical profile: quantification of 18 metabolites in short-echo-time (1)H NMR spectra of the rat brain. J. Magn. Reson. 141, 104-120. (Pubitemid 129608901)
110. Pouwels P. J., and, Frahm J., (1998) Regional metabolite concentrations in human brain as determined by quantitative localized proton MRS. Magn. Reson. Med. 39, 53-60. (Pubitemid 28028338)
111. Purdon S. E., Valiakalayil A., Hanstock C. C., Seres P., and, Tibbo P., (2008) Elevated 3T proton MRS glutamate levels associated with poor Continuous Performance Test (CPT-0X) scores and genetic risk for schizophrenia. Schizophr. Res. 99, 218-224.
112. Reid M. A., Stoeckel L. E., White D. M., Avsar K. B., Bolding M. S., Akella N. S., Knowlton R. C., den Hollander J. A., and, Lahti A. C., (2010) Assessments of function and biochemistry of the anterior cingulate cortex in schizophrenia. Biol. Psychiatry 68, 625-633.
113. Reig S., Moreno C., Moreno D., Burdalo M., Janssen J., Parellada M., Zabala A., Desco M., and, Arango C., (2009) Progression of brain volume changes in adolescent-onset psychosis. Schizophr. Bull. 35, 233-243.
114. Reiss A. L., Abrams M. T., Singer H. S., Ross J. L., and, Denckla M. B., (1996) Brain development, gender and IQ in children. A volumetric imaging study. Brain 119 (Pt 5), 1763-1774. (Pubitemid 26375742)
115. Rothermundt M., Ohrmann P., Abel S., et al,. (2007) Glial cell activation in a subgroup of patients with schizophrenia indicated by increased S100B serum concentrations and elevated myo-inositol. Prog. Neuropsychopharmacol. Biol. Psychiatry 31, 361-364. (Pubitemid 46209417)
116. Rothman D. L., Sibson N. R., Hyder F., Shen J., Behar K. L., and, Shulman R. G., (1999) In vivo nuclear magnetic resonance spectroscopy studies of the relationship between the glutamate-glutamine neurotransmitter cycle and functional neuroenergetics. Philos. Trans. R. Soc. Lond. B Biol. Sci. 354, 1165-1177. (Pubitemid 29400899)
117. Rowland L., Bustillo J. R., and, Lauriello J., (2001) Proton magnetic resonance spectroscopy (H-MRS) studies of schizophrenia. Semin. Clin. Neuropsychiatry 6, 121-130.
118. Rowland L. M., Spieker E. A., Francis A., Barker P. B., Carpenter W. T., and, Buchanan R. W., (2009) White matter alterations in deficit schizophrenia. Neuropsychopharmacology: official publication of the American College of. Neuropsychopharmacology 34, 1514-1522.
119. Rusch N., Tebartz van Elst L., Valerius G., Buchert M., Thiel T., Ebert D., Hennig J., and, Olbrich H. M., (2008) Neurochemical and structural correlates of executive dysfunction in schizophrenia. Schizophr. Res. 99, 155-163. (Pubitemid 351249108)
120. Sanches R. F., Crippa J. A., Hallak J. E., Araujo D., and, Zuardi A. W., (2004) Proton magnetic resonance spectroscopy of the frontal lobe in schizophrenics: a critical review of the methodology. Rev. Hosp. Clin. Fac. Med. Sao Paulo 59, 145-152.
121. Sanches R. F., Crippa J. A., Hallak J. E., de Sousa J. P., Araujo D., Santos A. C., and, Zuardi A. W., (2008) Proton magnetic resonance spectroscopy of the frontal, cingulate and perirolandic cortices and its relationship to skin conductance in patients with schizophrenia. Braz. J. Med. Biol. Res. 41, 1132-1141.
122. Seamans J. K., and, Yang C. R., (2004) The principal features and mechanisms of dopamine modulation in the prefrontal cortex. Prog. Neurobiol. 74, 1-58.
123. Shimizu E., Hashimoto K., Ochi S., et al,. (2007) Posterior cingulate gyrus metabolic changes in chronic schizophrenia with generalized cognitive deficits. J. Psychiatr. Res. 41, 49-56. (Pubitemid 44708200)
124. Sigmundsson T., Maier M., Toone B. K., Williams S. C., Simmons A., Greenwood K., and, Ron M. A., (2003) Frontal lobe N-acetylaspartate correlates with psychopathology in schizophrenia: a proton magnetic resonance spectroscopy study. Schizophr. Res. 64, 63-71. (Pubitemid 37153350)
125. Simmons M. L., Frondoza C. G., and, Coyle J. T., (1991) Immunocytochemical localization of N-acetyl-aspartate with monoclonal antibodies. Neuroscience 45, 37-45.
126. Stanley J. A., Williamson P. C., Drost D. J., Rylett R. J., Carr T. J., Malla A., and, Thompson R. T., (1996) An in vivo proton magnetic resonance spectroscopy study of schizophrenia patients. Schizophr. Bull. 22, 597-609. (Pubitemid 26389406)
127. Stanley J. A., Pettegrew J. W., and, Keshavan M. S., (2000) Magnetic resonance spectroscopy in schizophrenia: methodological issues and findings-part I. Biol. Psychiatry 48, 357-368.
128. Stanley J. A., Vemulapalli M., Nutche J., Montrose D. M., Sweeney J. A., Pettegrew J. W., MacMaster F. P., and, Keshavan M. S., (2007) Reduced N-acetyl-aspartate levels in schizophrenia patients with a younger onset age: a single-voxel 1H spectroscopy study. Schizophr. Res. 93, 23-32. (Pubitemid 46817964)
129. Steel R. M., Bastin M. E., McConnell S., Marshall I., Cunningham-Owens D. G., Lawrie S. M., Johnstone E. C., and, Best J. J., (2001) Diffusion tensor imaging (DTI) and proton magnetic resonance spectroscopy (1H MRS) in schizophrenic subjects and normal controls. Psychiatry Res. 106, 161-170. (Pubitemid 32520942)
130. Steen R. G., Hamer R. M., and, Lieberman J. A., (2005) Measurement of brain metabolites by 1H magnetic resonance spectroscopy in patients with schizophrenia: a systematic review and meta-analysis. Neuropsychopharmacology: official publication of the American College of. Neuropsychopharmacology 30, 1949-1962. (Pubitemid 43093497)
131. Stone J. M., Day F., Tsagaraki H., Valli I., McLean M. A., Lythgoe D. J., O'Gorman R. L., Barker G. J., and, McGuire P. K., (2009) Glutamate dysfunction in people with prodromal symptoms of psychosis: relationship to gray matter volume. Biol. Psychiatry 66, 533-539.
132. Supprian T., Hofmann E., Warmuth-Metz M., Franzek E., and, Becker T., (1997) MRI T2 relaxation times of brain regions in schizophrenic patients and control subjects. Psychiatry Res. 75, 173-182. (Pubitemid 28005226)
133. Szulc A. G., Tarasow B., Kubas E., Dzienis B., Walecki W., Czernikiewicz J., and, A., (2004) Glutamatergic system dysfunction in schizophrenia. A proton magnetic resonance spectroscopy (1H MRS) Study. Pol. J. Radiol. 69, 33-36.
134. Szulc A., Galinska B., Tarasow E., et al,. (2007) N-acetylaspartate (NAA) levels in selected areas of the brain in patients with chronic schizophrenia treated with typical and atypical neuroleptics: a proton magnetic resonance spectroscopy (1H MRS) study. Med. Sci. Monit. 13 (Suppl 1), 17-22.
135. Szulc A., Galinska B., Tarasow E., Waszkiewicz N., Konarzewska B., Poplawska R., Bibulowicz D., Simonienko K., and, Walecki J., (2011) Proton magnetic resonance spectroscopy study of brain metabolite changes after antipsychotic treatment. Pharmacopsychiatry 44, 148-157.
136. Tamagaki C., Sedvall G. C., Jonsson E. G., Okugawa G., Hall H., Pauli S., and, Agartz I., (2005) Altered white matter/gray matter proportions in the striatum of patients with schizophrenia: a volumetric MRI study. Am. J. Psychiatry 162, 2315-2321. (Pubitemid 41740210)
137. Tang C. Y., Friedman J., Shungu D., et al,. (2007) Correlations between Diffusion Tensor Imaging (DTI) and Magnetic Resonance Spectroscopy (1H MRS) in schizophrenic patients and normal controls. BMC Psychiatry 7, 25.
138. Tayoshi S., Sumitani S., Taniguchi K., et al,. (2009) Metabolite changes and gender differences in schizophrenia using 3-Tesla proton magnetic resonance spectroscopy (1H-MRS). Schizophr. Res. 108, 69-77.
139. Tayoshi S., Nakataki M., Sumitani S., et al,. (2010) GABA concentration in schizophrenia patients and the effects of antipsychotic medication: a proton magnetic resonance spectroscopy study. Schizophr. Res. 117, 83-91.
140. Théberge J., Bartha R., Drost D. J., et al,. (2002) Glutamate and glutamine measured with 4.0 T proton MRS in never-treated patients with schizophrenia and healthy volunteers. Am. J. Psychiatry 159, 1944-1946. (Pubitemid 35283267)
141. Théberge J., Al-Semaan Y., Williamson P. C., Menon R. S., Neufeld R. W., Rajakumar N., Schaefer B., Densmore M., and, Drost D. J., (2003) Glutamate and glutamine in the anterior cingulate and thalamus of medicated patients with chronic schizophrenia and healthy comparison subjects measured with 4.0-T proton MRS. Am. J. Psychiatry 160, 2231-2233. (Pubitemid 39619619)
142. Théberge J., Williamson P. C., Manchanda R., Menon R. S., Neufeld R. W., Densmore M., Williamson K. E., and, Drost D. J., (2004) Longitudinal Study of First-Episode Schizophrenia using 4.0T 1H MRS and Voxel-Based Morphometry. Proc. Intl. Soc. Mag. Reson. Med. 11, 523.
143. Théberge J., Jensen J. E., and, Rowland L. M., (2007a) Regarding "Increased prefrontal and hippocampal glutamate concentration in schizophrenia: evidence from a magnetic resonance spectroscopy study". Biol. Psychiatry 61, 1218-1219; author reply 1219-1220. (Pubitemid 46669453)
144. Théberge J., Williamson K. E., Aoyama N., et al,. (2007b) Longitudinal grey-matter and glutamatergic losses in first-episode schizophrenia. Br. J. Psychiatry 191, 325-334. (Pubitemid 47555981)
145. Tibbo P., Hanstock C., Valiakalayil A., and, Allen P., (2004) 3-T proton MRS investigation of glutamate and glutamine in adolescents at high genetic risk for schizophrenia. Am. J. Psychiatry 161, 1116-1118. (Pubitemid 38736001)
146. Tkac I., Andersen P., Adriany G., Merkle H., Ugurbil K., and, Gruetter R., (2001) In vivo 1H NMR spectroscopy of the human brain at 7 T. Magn. Reson. Med. 46, 451-456. (Pubitemid 32831318)
147. Tost H., Alam T., and, Meyer-Lindenberg A., (2010) Dopamine and psychosis: theory, pathomechanisms and intermediate phenotypes. Neurosci. Biobehav. Rev. 34, 689-700.
148. Tunc-Skarka N., Weber-Fahr W., Hoerst M., Meyer-Lindenberg A., Zink M., and, Ende G., (2009) MR spectroscopic evaluation of N-acetylaspartate's T2 relaxation time and concentration corroborates white matter abnormalities in schizophrenia. NeuroImage 48, 525-531.
149. Urenjak J., Williams S. R., Gadian D. G., and, Noble M., (1993) Proton nuclear magnetic resonance spectroscopy unambiguously identifies different neural cell types. J. Neurosci. 13, 981-989. (Pubitemid 23067586)
150. Vita A., De Peri L., Silenzi C., and, Dieci M., (2006) Brain morphology in first-episode schizophrenia: a meta-analysis of quantitative magnetic resonance imaging studies. Schizophr. Res. 82, 75-88. (Pubitemid 43202650)
151. Walter H., (2005) Funktionelle Bildgebung in Psychiatrie und Psychotherapie. Methodische Grundlagen und klinische Anwendungen. Schattauer GmbH, Stuttgart, New York.
152. Watts J., Fowler L., Whitton P. S., and, Pearce B., (2005) Release of arginine, glutamate and glutamine in the hippocampus of freely moving rats: Involvement of nitric oxide. Brain Res. Bull. 65, 521-528. (Pubitemid 40615910)
153. Weber-Fahr W., Ende G., Braus D. F., Bachert P., Soher B. J., Henn F. A., and, Buchel C., (2002) A fully automated method for tissue segmentation and CSF-correction of proton MRSI metabolites corroborates abnormal hippocampal NAA in schizophrenia. NeuroImage 16, 49-60. (Pubitemid 34852472)
154. Whittall K. P., MacKay A. L., Graeb D. A., Nugent R. A., Li D. K., and, Paty D. W., (1997) In vivo measurement of T2 distributions and water contents in normal human brain. Magn. Reson. Med. 37, 34-43. (Pubitemid 27008828)
155. Williamson P., Pelz D., Merskey H., Morrison S., Karlik S., Drost D., Carr T., and, Conlon P., (1992) Frontal, temporal, and striatal proton relaxation times in schizophrenic patients and normal comparison subjects. Am. J. Psychiatry 149, 549-551.
156. Wobrock T., Scherk H., and, Falkai P., (2005) Magnetic resonance spectroscopy in schizophrenia. Possibilities and limitations. Radiologe 45: 124-136. (Pubitemid 40379395)
157. Wood S. J., Berger G. E., Wellard R. M., Proffitt T., McConchie M., Velakoulis D., McGorry P. D., and, Pantelis C., (2008) A 1H-MRS investigation of the medial temporal lobe in antipsychotic-naive and early-treated first episode psychosis. Schizophr. Res. 102, 163-170.
158. Wood S. J., Berger G. E., Wellard R. M., Proffitt T. M., McConchie M., Berk M., McGorry P. D., and, Pantelis C., (2009) Medial temporal lobe glutathione concentration in first episode psychosis: a 1H-MRS investigation. Neurobiol. Dis. 33, 354-357.
159. Woodward N. D., Waldie B., Rogers B., Tibbo P., Seres P., and, Purdon S. E., (2009) Abnormal prefrontal cortical activity and connectivity during response selection in first episode psychosis, chronic schizophrenia, and unaffected siblings of individuals with schizophrenia. Schizophr. Res. 109, 182-190.
160. Yamasue H., Fukui T., Fukuda R., et al,. (2002) 1H-MR spectroscopy and gray matter volume of the anterior cingulate cortex in schizophrenia. NeuroReport 13, 2133-2137. (Pubitemid 36005940)
161. Yasukawa R., Miyaoka T., Mizuno S., Inagaki T., Horiguchi J., Oda K., and, Kitagaki H., (2005) Proton magnetic resonance spectroscopy of the anterior cingulate gyrus, insular cortex and thalamus in schizophrenia associated with idiopathic unconjugated hyperbilirubinemia (Gilbert's syndrome). J. Psychiatry Neurosci. 30, 416-422. (Pubitemid 41812488)
162. Yoo S. Y., Yeon S., Choi C. H., et al,. (2009) Proton magnetic resonance spectroscopy in subjects with high genetic risk of schizophrenia: investigation of anterior cingulate, dorsolateral prefrontal cortex and thalamus. Schizophr. Res. 111, 86-93.
163. Yoon J. H., Maddock R. J., Rokem A., Silver M. A., Minzenberg M. J., Ragland J. D., and, Carter C. S., (2010) GABA concentration is reduced in visual cortex in schizophrenia and correlates with orientation-specific surround suppression. J. Neurosci. 30, 3777-3781.
164. Yucel M., Stuart G. W., Maruff P., Velakoulis D., Crowe S. F., Savage G., and, Pantelis C., (2001) Hemispheric and gender-related differences in the gross morphology of the anterior cingulate/paracingulate cortex in normal volunteers: an MRI morphometric study. Cereb. Cortex 11, 17-25. (Pubitemid 32064173)
165. Yucel M., Lubman D. I., Harrison B. J., et al,. (2007) A combined spectroscopic and functional MRI investigation of the dorsal anterior cingulate region in opiate addiction. Mol. Psychiatry 12, 611; 691-702. (Pubitemid 46998248)
166. Zaaraoui W., Fleysher L., Fleysher R., Liu S., Soher B. J., and, Gonen O., (2007) Human brain-structure resolved T(2) relaxation times of proton metabolites at 3 Tesla. Magn. Reson. Med. 57, 983-989. (Pubitemid 46911283)
167. Zabala A., Sanchez-Gonzalez J., Parellada M., Moreno D. M., Reig S., Burdalo M. T., Robles O., Desco M., and, Arango C., (2007) Findings of proton magnetic resonance spectometry in the dorsolateral prefrontal cortex in adolescents with first episodes of psychosis. Psychiatry Res. 156, 33-42. (Pubitemid 47375071)